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OBJECTIVES: To examine the economic burden and health care resource utili-
zation of myeloproliferative neoplasms (MPNs) in the U.S. Medicare popula-
tion. METHODS: A retrospective data analysis was performed using the U.S. 
national Medicare claims from January 2008 through December 2012. MPN patients 
were identified using International Classification of Disease 9th Revision Clinical 
Modification (ICD-9-CM) diagnosis codes 238.4, 238.71, 238.76 and 289.83. The diag-
nosis date was designated as the index date. A comparison cohort without a MPN 
diagnosis was created for patients of the same age, region, gender, index year and 
baseline Charlson Comorbidity Index score. A random index date was chosen for 
the comparison cohort to reduce selection bias. Patients were required to have 
continuous medical and pharmacy benefits 1 year pre- and post-index date. One-
to-one propensity score matching (PSM) was performed to compare follow-up 
health care costs and utilizations between the cohorts, adjusting for demographic 
and clinical characteristics. RESULTS: Eligible patients (N= 17,950) were identified 
for the MPN and comparison cohorts. After 1:1 PSM, a total of 5,546 patients were 
matched from each cohort and baseline characteristics were well-balanced. MPN 
patients had a higher percentage of health care resource utilizations, including 
Medicare carrier (98.6% vs. 65.9%), Durable Medical Equipment (DME; 29.5% vs. 
14.4%), Home Health Agency (HHA; 12.4% vs. 5.0%), outpatient visits (76.6% vs. 
37.4%), inpatient hospitalizations (27.2% vs. 6.8%) and Skilled Nursing Facility (SNF; 
7.5% vs. 2.0%) visits than non-MPN patients. Patients diagnosed with MPNs also 
incurred significantly higher costs, including Medicare carrier ($3,872 vs. $1,283), 
DME ($266 vs. $91), HHA ($639 vs. $250), outpatient ($10,061 vs. $3,204), inpatient 
($5,449 vs. $1,054), pharmacy ($1,069 vs. $713) and total health care costs ($23,060 
vs. $7,076; p< 0.0001). CONCLUSIONS: MPN patients had a higher burden of illness 
compared to non-MPN patients.
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OBJECTIVES: Drug toxicities and adverse events (AE) during cancer treatment pre-
sent a significant economic burden to health systems. Post 2007 there has been no 
systematic review summarizing the costs of AEs related to chemotherapy. Hence, 
the objective of this study is to provide an updated understanding of the cost of 
AEs in cancer treatments in the US. METHODS: A systematic literature search 
was conducted using PubMed. Selection criteria included studies published in 
the English language between January 2008 and October 2013, evaluating the cost 
of following AEs: neutropenia, thrombocytopenia, vomiting, nausea, peripheral 
neuropathy, sepsis, diarrhea and fatigue/asthenia, due to cancer treatment in the 
US. Costs were extracted for case and control cohorts (if available) and the cost 
difference between the cohorts was calculated to provide the additional cost due 
to the AEs. This difference in costs was then adjusted to 2013 USD. RESULTS: A 
total of 893 abstracts were screened, of which 15 unique studies were included. 
The distribution of studies reporting the selected AEs were: neutropenia (n= 5), 
thrombocytopenia (n= 3), vomiting (n= 1), nausea/vomiting (n= 4), peripheral neu-
ropathy (n= 1), sepsis (n= 2), diarrhea (n= 1) and fatigue/asthenia (n= 1). The stud-
ies reported inpatient, outpatient, or total healthcare costs, with different units 
including per patient, per-patient per-year (PPPY), per event or per episode. AE 
costs varied vastly; the per event cost ranged from $213 (outpatient) to $6,000 
(inpatient) while the PPPY cost ranged from $9,800 (outpatient) to $21,000 (total 
healthcare costs). CONCLUSIONS: AEs commonly encountered in cancer treat-
ment remain an expensive problem despite medical advances. In addition to the 
high cost of cancer treatment, the cost of managing AEs adds to the economic 
burden on patients, Payers, and society. This study highlights that the cost of AEs 
associated with cancer treatments are consistently high and consume a large 
portion of healthcare resources.
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OBJECTIVES: Branded biologics will soon begin to face competition from incoming 
biosimilar monoclonal antibodies (mAbs), with many currently in development. 
Given the transition many markets are making towards becoming increasingly cost 
conscious, we sought to investigate how budget holders across the most important 
European markets perceived the incoming oncology biosimilar mAbs. METHODS: 
The research was conducted through in-depth interviews and focus groups with 
budget holders and clinicians across the EU5. RESULTS: All respondents had previ-
ous experience evaluating and making decisions on small molecule biosimilars (e.g. 
filgrastim, EPO). However, there was a lack of experience and knowledge amongst 
EU5 budget holders with biosimilar mAbs and they were unsure how or by whom 
they were going to be educated. The originator product was preferred in all attributes 
tested while costs were cited as the most important driver for encouraging adop-
tion of biosimilar mAbs. Additionally, budget holders across the EU5 were adamant 
about encouraging automatic substitution (albeit, initially only for new patients), of 
the originator until enough experience was built up (at least 12 months, 24 months 
likely). Respondents also suggested that key institutions or regions will make deci-
sions early on while other less resourced centres/regions will adopt their decision. 
Conversely, clinicians were apprehensive of biosimilar mAbs and anticipate resisting 
to contemplate The question how innovative technologies can be financed is there 
even more pronounced. We estimated the direct medical costs of breast cancer treat-
ment in Iran in the period of 21/03/2011-20/03/2014 and examined the fraction of 
total costs related to trastuzumab use. METHODS: A retrospective claims database 
analysis was performed using data from the Iran Social Security Organization, a 
health insurer which covers approximately 50% of the Iranian population. Data min-
ing techniques helped to identify patients and determine resource use in the three 
stages of breast cancer (early, loco-recurrence and advanced). Using a healthcare 
perspective, absolute and relative costs of various medical services associated with 
treatment of HER2-positive breast cancer among Iranian women in both public and 
private healthcare systems were calculated. RESULTS: The patient population com-
prised 1295 women (mean (SD) age: 45.6 (10.3) years) and mean follow-up was 739 
days (range:21-1072). Average costs of drugs and chemotherapy in early, loco-recur-
rence and advanced stages were € 2,707 (range:€ 98-€ 23,680), € 2,751 (€ 31-€ 23,420) and 
€ 13,030 (€ 115-€ 45,833), respectively. Average costs of radiotherapy and diagnostic 
tests were € 2,138 (€ 5-€ 49,534), € 516 (€ 2-€ 9,064) and € 507 (€ 6-€ 17,125). Trastuzumab 
accounted for the largest share of total costs (58%), followed by paraclinical services 
(12%), radiotherapy (10%), and other drugs and chemotherapy (9%). CONCLUSIONS: 
Trastuzumab is an expensive drug may which require a substantial share of avail-
able budgets. These cost estimates can be included in cost-effectiveness analyses 
to determine if these costs are justified from a health economic view. Moreover, if 
relevant data are available, data mining techniques can support real-world cost-
effectiveness analyses in middle-income countries and thereby help to optimize 
reimbursement decisions.
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OBJECTIVES: An estimated 17 million people in the US have Barrett’s Esophagus 
(BE), a precursor to esophageal cancer (EAC). The low probability of progressing 
to EAC (less than 2%) and the inability of standard histopathology to risk stratify 
BE patients have resulted in inefficient surveillance protocols and calls for effec-
tive innovation to identify higher risk patients. A newly-developed biomarker 
test can risk stratify BE patients for progression to high grade dysplasia (HGD) 
and EAC. The test stratifies patients into high, medium and low risk categories, 
giving providers actionable information for BE endoscopy surveillance frequency 
and treatment decisions such as radiofrequency ablation (RFA). This study evalu-
ates the cost-effectiveness of this new biomarker test compared with the current 
standard of care (SOC) surveillance and treatment of BE. METHODS: Decision 
analysis with Markov modeling and cohort simulation were used to model treat-
ment costs and outcomes from a health plan perspective. Costs were derived from 
Geisinger Health Plan claims data and quality-adjusted life-years (QALYs) from 
the medical literature. The model includes realistic assumptions for physician 
adherence to SOC for patients in each risk category. RESULTS: Preliminary results 
of a 5 year model of using the new biomarker test compared to SOC include an 
incremental cost-effectiveness ratio of $75,804 in U.S. 2012 dollars. Cumulative 
endoscopies in the biomarker test arm were 6.23% greater than with SOC and 
there were 73.3% fewer cumulative RFAs under SOC than with the biomarker 
test. Compared with SOC, the number of patients in the HGD, EAC, and death 
states in the biomarker test arm were 52.5%, 60.9% and 9.83% fewer, respec-
tively. CONCLUSIONS: Using this new biomarker test to risk stratify BE patients 
is cost-effective at the $100,000 threshold and, due to more effective surveillance 
and treatment protocols, results in fewer patients transitioning to HGD, EAC, and 
death.
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OBJECTIVES: To evaluate the health care resource utilization and economic burden 
of non-Hodgkin’s lymphoma (NHL) in the U.S. Medicare population. METHODS: 
NHL patients were identified (International Classification of Diseases, 9th Revision, 
Clinical Modification [ICD-9-CM] diagnosis codes 200.xx and 202.xx) using national 
U.S. Medicare claims from January 1, 2009 through December 31, 2011. The first diag-
nosis date was designated as the index date for the NHL cohort. Control patients of the 
same age, region, gender and index year were identified and matched to case patients 
based on baseline Charlson Comorbidity Index (CCI) scores, and were assigned a ran-
domly chosen index date to minimize selection bias. Patients were required to have 
continuous medical and pharmacy benefits 1 year pre- and post-index date. Study 
outcomes, including health care costs and utilizations, were compared between the 
disease and comparison cohorts using 1:1 propensity score matching (PSM). RESULTS: 
A total of 20,254 patients were included in the NHL and comparison cohorts. After 
1:1 PSM, 4,705 patients were matched from each cohort and baseline characteristics 
were balanced. Patients diagnosed with NHL were more likely to utilize health care 
resources including Medicare carrier (99.0% vs. 70.5%), Durable Medical Equipment 
(DME, 28.1% vs. 17.7%), Home Health Agency (HHA, 11.4% vs. 4.8%), outpatient visits 
(80.2% vs. 41.0%), inpatient stays (25.7% vs. 7.4%) and Skilled Nursing Facility (SNF, 
4.8% vs. 1.7%) and hospice admissions (0.9% vs. 0.3%). Patients diagnosed with NHL 
also incurred higher Medicare carrier ($10,603 vs. $1,522), DME ($264 vs. $120), HHA 
($531 vs. $270), outpatient ($30,013 vs. $4,268), inpatient ($5,762 vs. $1,167), SNF ($875 
vs. $307), hospice ($197 vs. $67), pharmacy ($1,050 vs. $785) and total costs ($49,296 
vs. $8,507; p< 0.005). CONCLUSIONS: The economic burden and health care resource 
utilizations were significantly higher for patients diagnosed with NHL compared to 
patients without NHL.
